Gene · 9682
Papers1,858
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 1,858
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| A novel disulfidptosis-related lncRNA signature for predicting prognosis and potential targeted therapy in hepatocellular carcinoma. | Medicine (Baltimore) | 2024 | 38277541 | PubTator, text mining | PubMed |
Unraveling the underlying pathogenic factors driving nonalcoholic steatohepatitis and hepatocellular carcinoma: an in-depth analysis of prognostically relevant gene signatures in hepatocellular carcinoma. | J Transl Med | 2024 | 38238845 | PubTator, text mining | PubMed |
| Androgen-repressed lncRNA LINC01126 drives castration-resistant prostate cancer by regulating the switch between O-GlcNAcylation and phosphorylation of androgen receptor. | Clin Transl Med | 2024 | 38214432 | PubTator, text mining | PubMed |
| A cyclin D1 intrinsically disordered domain accesses modified histone motifs to govern gene transcription. | Oncogenesis | 2024 | 38191593 | PubTator, text mining | PubMed |
| A disulfidptosis-related lncRNAs signature in hepatocellular carcinoma: prognostic prediction, tumor immune microenvironment and drug susceptibility. | Sci Rep | 2024 | 38185671 | PubTator, text mining | PubMed |
| Epigenetic OCT4 regulatory network: stochastic analysis of cellular reprogramming. | NPJ Syst Biol Appl | 2024 | 38184707 | PubTator, text mining | PubMed |
| Decoding human cytomegalovirus for the development of innovative diagnostics to detect congenital infection. | Pediatr Res | 2024 | 38146009 | PubTator, text mining | PubMed |
| Therapeutic potential of natural antisense transcripts and various mechanisms involved for clinical applications and disease prevention. | RNA Biol | 2024 | 38090817 | PubTator, text mining | PubMed |
Retraction: Cui S-Z, Lei Z-Y, Guan T-P, et al. Targeting USP1-dependent KDM4A protein stability as a potential prostate cancer therapy. Cancer Science. 2020; 111: 1567-1581. https://doi.org/10.1111/cas.14375. | Cancer Sci | 2024 | 38078665 | PubTator, text mining | PubMed |
| Oncogenic Cells of Renal Embryonic Lineage Sensitive to the Small-Molecule Inhibitor QC6352 Display Depletion of KDM4 Levels and Disruption of Ribosome Biogenesis. | Mol Cancer Ther | 2024 | 37988559 | PubTator, text mining | PubMed |
| Copy number loss of KDM5D may be a predictive biomarker for ATR inhibitor treatment in male patients with pulmonary squamous cell carcinoma. | J Pathol Clin Res | 2024 | 37974379 | PubTator, text mining | PubMed |
| LncRNAs-circRNAs as Rising Epigenetic Binary Superstars in Regulating Lipid Metabolic Reprogramming of Cancers. | Adv Sci (Weinh) | 2024 | 37939296 | PubTator, text mining | PubMed |
| KDM4B: A promising oncology therapeutic target. | Cancer Sci | 2024 | 37923555 | PubTator, text mining | PubMed |
| The role of KDM4A-mediated histone methylation on temozolomide resistance in glioma cells through the HUWE1/ROCK2 axis. | Kaohsiung J Med Sci | 2024 | 37873881 | PubTator, text mining | PubMed |
| The emerging roles of lysine-specific demethylase 4A in cancer: Implications in tumorigenesis and therapeutic opportunities. | Genes Dis | 2024 | 37692513 | PubTator, text mining | PubMed |
| The ubiquitin codes in cellular stress responses. | Protein Cell | 2024 | 37470788 | PubTator, text mining | PubMed |
| Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications. | Front Immunol | 2023 | 38268926 | PubTator, text mining | PubMed |
| Metabolic Enzymes in Viral Infection and Host Innate Immunity. | Viruses | 2023 | 38257735 | PubTator, text mining | PubMed |
| Noval advance of histone modification in inflammatory skin diseases and related treatment methods. | Front Immunol | 2023 | 38235133 | PubTator, text mining | PubMed |
| A methylation-related signature for predicting prognosis and sensitivity to first-line therapies in gastric cancer. | J Gastrointest Oncol | 2023 | 38196539 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9682/papers?page=6